Trial · NCT03974867

Vestibular Prognosis Assessment of ISSNHL With Vestibular Dysfunction Treated With Oral or Intratympanic Glucocorticoids

NCT03974867, Not applicable, Unknown, Eye & ENT Hospital of Fudan University

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Vestibular Prognosis Assessment of ISSNHL With Vestibular Dysfunction Treated With Oral or Intratympanic Glucocorticoids. Trials, record NCT03974867. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03974867

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Vestibular Prognosis Assessment of ISSNHL With Vestibular Dysfunction Treated With Oral or Intratympanic Glucocorticoids
NCT number: NCT03974867
Status: Unknown
Phases: Not applicable
Enrollment: 72 participants, estimated
Lead sponsor: Eye & ENT Hospital of Fudan University
Conditions: Vestibular Vertigo, Sudden Hearing Loss
Interventions: Prednisone 5Mg Tab, Methylprednisolone 40 mg
First posted: 2019-06-05
Last updated: 2019-07-24

Source ClinicalTrials.gov

Registered outcomes23

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Complete recovery rates of vestibular function tests within 8 weeks	8 weeks from baseline	To evaluate the recovery of vestibular function and subjective vestibular dysfunction feelings, we set the recovery rates of the whole battery of vestibular function tests (SOT/caloric test/vHIT/VEMPs) as the primary outcome, which is the proportion of patients whose abnormal results of vestibular function tests at baseline recover to normal during the 8-weeks follow-up: recovery rate (8 weeks)=(number of patients recover from abnormal result at baseline to normal during at 8-weeks follow-up)/(number of all enrolment participants patients with abnormal result at baseline)×100%;
Secondary	Change of SOT vestibular scores at 4-week follow-up	4 weeks from baseline	Change of the vestibular scores in SOT at 4-week follow-up from baseline
Secondary	Change of SOT vestibular scores at 8-week follow-up	8 weeks from baseline	Change of the vestibular scores in SOT at 8-week follow-up from baseline
Secondary	Change of unilateral weakness of caloric test at 4-week follow-up	4 weeks from baseline	Change of unilateral weakness (UW) of caloric test at 4-week follow-up
Secondary	Change of unilateral weakness of caloric test at 8-week follow-up	8 weeks from baseline	Change of UW of caloric test at 8-week follow-up
Secondary	Recovery rate of vHIT at 4-week follow-up	4 weeks from baseline	Recovery rate of vHIT at 4-week follow-up
Secondary	Recovery rate of vHIT at 8-week follow-up	8 weeks from baseline	Recovery rate of vHIT at 8-week follow-up
Secondary	Recovery rate of cVEMP at 4-week follow-up	4 weeks from baseline	Recovery rate of cVEMP at 4-week follow-up
Secondary	Recovery rate of cVEMP at 8-week follow-up	8 weeks from baseline	Recovery rate of cVEMP at 8-week follow-up
Secondary	Recovery rate of oVEMP at 4-week follow-up	4 weeks from baseline	Recovery rate of oVEMP at 4-week follow-up

1 to 10 of 23Source ClinicalTrials.gov

See all 23 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers5

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
21610239	BACKGROUND	PubMed
22383545	BACKGROUND	PubMed
29459846	BACKGROUND	PubMed
29931169	BACKGROUND	PubMed
32698830	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03974867

GET https://conductscience.org/api/trials/v1/NCT03974867/registered?page=2

API reference For AI assistants